Tumor-infiltrating lymphocytes are key mediators of tumor immune surveillance and are important prognostic indicators in cancer progression. Among the various lymphocyte subsets implicated in protection against cancer are gd T lymphocytes, which can kill tumor cells and secrete potent antitumor cytokines. By contrast, recent reports have revealed an unexpected series of protumor functions of gd T cells in mouse models and human patients. In particular, specific gd T-cell subsets are capable of recruiting immunosuppressive myeloid populations, inhibiting antitumor responses, and enhancing angiogenesis, thus promoting cancer progression. A common mediator of such functions appears to be the cytokine IL17, whose pathogenic effects can override the antitumor immune response orchestrated by IFNg. Here, we review these studies and discuss their implications for the manipulation of gd T cells in cancer immunotherapy. Cancer Res; 75(5); 798-802. Ó2015 AACR.
Longstanding Protective Roles of gd T Cells in Cancer Surveillance
The hallmarks of cancer have been recently revised to include an immune escape component that presumably overrides surveillance by tumor-infiltrating lymphocytes (TIL). Since the pioneering work of Girardi and colleagues (1) on chemically induced tumors in mice, rapidly followed by other studies on transplantable, transgenic, and even spontaneous tumors (reviewed in ref. 2) , gd T cells have been seen as prototypic antitumor TILs. These protective functions derive from T-cell receptor (TCR)-and natural killer (NK) receptor-mediated tumor cell recognition and gd T-cell activation, cytotoxicity and production of cytokines like TNF and IFNg (2) . Consistent with these properties, mice lacking gd T cells have been shown to develop faster and bigger tumors in models such as the transplantable B16 melanoma (3, 4) . It should be noted, however, that gd T cells subsets and their functional attributes differ significantly between mice and humans, which should qualify the conclusions drawn from mouse tumor models.
In humans, both major subsets of gd T cells, either Vd1 þ (predominant in tissues) or Vd2 þ (predominant in the circulation), are also cytolytic against solid and hematologic tumors, and produce high amounts of IFNg and TNF upon activation. This has fuelled a series of clinical trials targeting gd T cells, more specifically the blood-abundant Vg9Vd2 population, either endogenously or upon adoptive cell transfer. The most promising results (with objective responses up to 33%) were obtained upon in vivo administration of aminobisphosphonates, like zoledronate or pamidronate (5, 6) . These FDA-authorized drugs are known to selectively stimulate Vg9Vd2 T cells through metabolic accumulation of intracellular isopentenyl pyrophosphate, an agonist of the Vg9Vd2 TCR (7). We and others have also studied Vd1 þ T cells, which have been found in increased numbers and with enhanced antitumor functionality (when compared with Vd2 þ cells) in melanoma and leukemia (8) (9) (10) . Despite these interesting findings, the therapeutic potential of Vd1 þ T cells is still to be tested in the clinic.
Emerging Pathogenic Roles of gd T Cells in Cancer Progression
Tumor-promoting functions of gd T cells in mice and humans Despite the well-established concept of gd T cells as potent antitumor TILs, a study in 2007 on human breast cancer surprisingly revealed a potential protumor function (11) . gd T cells isolated from breast cancer biopsies were reported to inhibit the function of several immune cell populations in vitro, and consequently suppress their antitumor responses (11) . Consistent with these observations, the presence of gd T cells was shown to positively correlate with advanced tumor stages and inversely correlate with patient survival (12) . Of note, gd T cells represented the most significant independent prognostic factor for assessing severity of breast cancer (12) .
In mice, two distinct populations of gd T cells were shown to play opposite roles in melanoma progression. Whereas the Vg4 þ cells displayed several antitumor properties, the Vg1 subset were able to suppress Vg4 þ cells promoting tumor escape (13) .
These findings raised the interesting question as to whether different gd T-cell subsets could exert strikingly distinct antitumor versus protumor roles. The relatively recent identification of an additional functional subset of gd T cells, able to produce IL17 rather than IFNg, fostered the exploration of its functions in homeostasis and disease (14) . We have shown that commitment to production of IL17 or IFNg is determined in the thymus at epigenetic and transcriptional levels and is maintained in peripheral responses to several infectious microbes (14, 15) . This dichotomy of cytokine secretion segregates with CD27, the expression of which is associated with IFNg production, whereas IL17 production is restricted to CD27 À gd T cells (14) (15) (16) . In 2010, gd T cells were described as the main IL17-producing population in a murine fibrosarcoma model, in which they were suggested to promote tumor growth (17) . Subsequently, in 2011, gd T cells were similarly described as the main producers of IL17 in a lung metastasis model with detrimental effects for the tumorbearing host (18) . Recent reports using TCRd À/À mice have also demonstrated the protumor effects of gd T cells in hepatocellular carcinoma and ovarian cancer models, again correlated with IL17 production (19, 20) .
In contrast with the significant emerging literature describing the potential protumor effector function of IL17 þ gd T cells in murine models, reports on their human counterparts are still scarce. In 2011, a pioneering study showed that human gd T cells produced IL17 in response to bacterial meningitis, an extreme inflammatory condition (21) . Recently, IL17 þ gd T cells were also shown to accumulate in human colorectal cancer as compared to normal tissue (22) . In this context, gd T cells were the main source of IL17, and unlike CD4 þ Th17 cells, appeared to positively correlate with advanced stages of disease (22) . Furthermore, IL17 þ gd T cells have been also observed to be elevated in peripheral blood, as well as in the tumor tissue, of patients with gallbladder cancer (Dr. S.V. Chiplunkar, Tata Memorial Centre, Mumbai, India, personal communication). Collectively, these reports establish a new perspective on the contribution of gd T cells to tumor development, which highlights the importance of studying the full range of gd T-cell effector functions in preclinical animal models. Various different mechanisms have been proposed to mediate the protumor behavior of gd TILs in several tumor models ( Fig. 1 ), which will be described below.
Inhibition of antitumor responses
Tumor-infiltrating gd T cells have been described to inhibit the response of several immune cell populations against tumors. Human Vd1 þ gd T cells isolated from breast cancer biopsies inhibit proliferation of na€ ve T cells as well as IL2 production by effector CD4 þ and CD8 þ T cells (11 Promotion of angiogenesis gd T cells were first suggested to promote angiogenesis via IL17 production in the murine CMS-G4 fibrosarcoma model (17) . Using IL17 À/À mice, the authors demonstrated that IL17 is a key factor for optimal tumor growth in vivo. In the absence of IL17, fibrosarcoma tumors grow slower and with a reduced number of blood vessels (17) . Moreover, in vitro provision of IL17 increased the expression of the angiogenic-related genes ang-2 and vegf in CMS-G4 cells (17) . Similarly, in the ID8 ovarian cancer model, tumors grown in IL17 À/À and TCRd À/À mice express lower levels of ang-2 and vegf when compared with tumors grown in wild-type animals (20) . IL17 þ gd T cells also support the mobilization of proangiogenic Tie2-expressing macrophages into the peritoneal cavity (20) . In an oncogenic KRAS
G12D
-driven pancreatic cancer model, IL17 produced by both Th17 and gd T cells is associated with increased IL6/Stat3 signaling, which was previously shown to upregulate prosurvival and proangiogenic genes (24, 25) .
Recruitment of protumor myeloid populations
IL17 þ gd T cells were demonstrated to mediate the mobilization of myeloid-derived suppressor cells (MDSC), which subsequently reduce cytotoxic responses by CD8 þ T cells, in a mouse model of hepatocellular carcinoma (19) . Experiments in vitro suggest that IL17 upregulates CXCL5 expression on a murine hepatoma cell line that increases the migration of MDSC through interaction with CXCR2 (19) . IL17 was also shown to enhance the immunosuppressive functions of MDSC (19) . Interestingly, a similar capacity of IL17 þ gd T cells to recruit MDSC was described in human colorectal cancer (22) . In this study, gd T cells promoted in vitro migration, proliferation, and survival of MDSC via production of IL17, IL8, GM-CSF, and TNFa (22) . Our recent work has demonstrated that IL17 þ gd T cells also promote the mobilization of blood-derived small peritoneal macrophages (SPM) into the peritoneal cavity upon ID8 ovarian cancer cell transplantation (20) . SPMs have a proinflammatory and proangiogenic gene-expression profile and are able to directly enhance ID8 tumor cell growth in vitro (20) .
The key role of IL17 in the protumor functions of gd T cells IL17 is a common mediator of the gd T-cell protumor function in several of the aforementioned studies. Interestingly, in some of these, IFNg-producing gd T cells are also reported to accumulate in the tumor environment (20, 22, 24) . A dominant effect of IL17 over IFNg was previously reported, and may explain the net protumor effect of gd T cells when IL17 is produced (25) . For example, in murine models of melanoma and bladder cancer, the slow growth of tumors in double knockout IL17 À/À .IFNg À/À mice resembles the IL17 À/À phenotype rather than the fast growing phenotype of IFNg À/À animals (25). Expression of IL22 was also observed in tumor-infiltrating gd T cells in a murine fibrosarcoma model as well as in human pancreatic cancer. However, IL22 transcripts were not detected in human colorectal carcinomainfiltrating gd T cells (17, 22, 24) . However, the relevance of this cytokine or other Th17 cytokines, such as IL17F, that may be produced by gd T cells in cancer has been poorly addressed. IL17 production seems to be restricted to specific subsets of gd T cells, which are preferentially expanded in the tumor environment. In a hepatocellular carcinoma model, the majority of IL17 þ gd T cells express the Vg4 chain and have the typical (19) . By contrast, the IL17 þ gd T cells that accumulate in the ID8 ovarian cancer model express the Vg6 chain (20) . In human colorectal cancer, tumor-infiltrating
, and display an effector memory (CD45RA À and CD27 À ) phenotype (22) . Tumor microenvironment-derived cytokines have been shown to trigger IL17 polarization in gd T cells. In a fibrosarcoma model, inhibition in vivo of the Th17-polarizing cytokines IL6, TGFb, and IL23 using blocking antibodies partially reduced the percentage of tumor-infiltrating IL17 þ gd T cells (17) . In a lung metastasis model, IL1b was shown to recruit and polarize gd T cells toward IL17 production (18) . In a murine hepatocellular carcinoma model, depletion in vivo of MDSCs reduced tumor-infiltrating IL17 þ gd T cells, possibly as a result of the absence of MDSCderived IL1b and IL23 (19) . Similarly, in human colorectal cancer, DC-derived IL23 was proposed to polarize gd T cells toward IL17 production (22) . In an ovarian cancer model, a combined effect of IL7, IL6, and IL1b was suggested to drive the selective expansion of IL17 þ gd T cells (20) . Furthermore, oncogenic KRAS G2D -expressing pancreatic cells were shown to recruit IL17-producing gd T cells into the pancreatic malignant environment via IL6 production, which accelerated the initiation and progression of pancreatic cancer (24) . Experiments ex vivo suggest that TCRgd signaling may also be required for IL17 production by gd T cells (17, 26) . Moreover, the preferential expansion in several models of IL17 þ gd T cells with a limited receptor repertoire (19, 20, 22) , suggests that an additional TCR-mediated mechanism may also be involved.
Future Perspectives for gd T-cell-Based Cancer Immunotherapy
The therapeutic implications of the pleiotropic biologic interactions between gd T cells and tumors still remain unclear. Nonetheless, the recent discovery of protumor roles for particular gd T-cell populations may create new challenges for future therapeutic approaches. Thus, for both stimulation in vivo and activation in vitro (for adoptive transfer), it will be important to evaluate the stable functional polarization of effector gd T cells. On the basis of the most available data, we argue that clinical protocols should maximize IFNg production and minimize IL17 secretion. However, it should be noted that murine IL17-producing gd T cells have also been implicated in protective responses in some particular tumor scenarios. For example, they seemingly contributed to the therapeutic effect of doxorubicin in various transplantable models of epithelial tumors in vivo (27) . The authors proposed a link between IL17 and the priming (in the draining lymph nodes) of an IFNg response by CD8 þ T cells, (10, 11) . We are therefore particularly interested in exploring the therapeutic potential of Vd1 þ cells, particularly as no clinical trial has yet focused on this gd T-cell subset.
Of note, the success of gd T-cell-based immunotherapy is also likely to depend on avoiding activation-induced cell death and exhaustion of the gd T-cell compartment, and on overcoming inhibitory mechanisms as those posed by PD-1 expression (30) or the suppressive functions of regulatory T cells (31, 32) .
Finally, we think it will be important to evaluate the prognostic value of gd T-cell subsets (such as IFNg þ vs. IL17 þ ) in biopsies of various cancer types to assess their added value to the so-called immunoscore (33) and its capacity to inform oncologists and immunologists toward efficient immunotherapies against malignant tumors.
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